RxDoctor Payments Data

Nathan Klein

Optometrist · Memphis, TNNPI 1457792350

Payments from drug & device makers

$5,277in general payments, 2019–2025

Across 279 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Sun Pharmaceutical Industries Inc.$886
  • Bausch & Lomb Americas Inc.$660
  • Tarsus Pharmaceuticals, Inc.$381
  • Eyevance Pharmaceuticals LLC$362
  • Kala Pharmaceuticals, Inc.$285
  • plus $2K from 15 others

What the payments were for

  • Travel & lodging$2475%
  • Food & beverage$5,03095%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,277 in reported general payments places this provider in the 90th percentile of 1,122 optometrist providers in Tennessee.

See all optometrist providers in Tennessee

Medicare billing

Part B allowed, 2024
$153,765
Medicare patients
363
Services billed
1,945

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj13$701,706
CequaCyclosporine46$42,107
MieboPerfluorohexyloctane/Pf16$16,572
XiidraLifitegrast15$15,664
LumiganBimatoprost15$9,756
VyzultaLatanoprostene Bunod18$6,834
EysuvisLoteprednol Etabonate11$5,254
Tobramycin-DexamethasoneTobramycin/Dexamethasone87$3,734
Latanoprost82$924
Prednisolone Acetate31$836
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat47$683
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha65$607
MoxifloxacinMoxifloxacin Hcl23$403
Doxycycline Hyclate28$296
Timolol Maleate11$84

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$147$701,70613 claims
Sun Pharmaceutical Industries Inc.Cequa$886$42,10746 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta$660$39,07049 claims
AbbVieLumigan$140$9,75615 claims
Kala Pharmaceuticals, Inc.Eysuvis$285$5,25411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,122 optometrist providers in Tennessee.

Other optometrist in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →